Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently
Moved to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Mikhail Blagosklonny published dozens of experimental research articles and theoretical articles as lead
Author. The abovementioned sole-author papers
Included two important themes.
The first of those discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Verifying their resistance. The outcomes and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the publication was
Titled, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research method to develop knowledge via
Uniting a few facts together from seemingly unrelated areas.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant result revealed by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Inhibiting body aging — in other words, “preventing cancer
By remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of additional anti-aging
Medications besides rapamycin. The cell culture studies were
Complemented by studies in mice, including a few models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging drugs to be taken by humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.